SILVER SPRING, Md., June 26 (Reuters) - River Plate Biotechnology did not provide adequate evidence of safety and effectiveness for a proposed drug to treat dry eye, a U.S. advisory panel ruled on Friday.
The committee voted 6-1 against the drug, called Rejena. Alcon Inc (ACL.N) holds U.S. marketing rights for the product.
(Reporting by Lisa Richwine)
© Thomson Reuters 2009 All rights reserved
The "Dubai model" -- building shining cities in the desert at breakneck speed through the import of foreign residents, finance and labor -- is now on the ropes. Full Article
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
